EU project IMMIDIET warns: control hypertension in Europe

An EU-funded population study has shown that hypertension, an important risk factor for cardiovascular disease, is a serious problem in Europe. The results of the IMMIDIET project indicate that high blood pressure has become more common in Italy than in England or Belgium, a reversal of the commonly accepted trend. They also demonstrate that awareness is quite limited, and that those who are diagnosed do not adequately manage their condition. The results have been published online in the Journal of Hypertension.

The IMMIDIET project ('Dietary habit profile in European communities with different risk of myocardial infarction: the impact of migration as a model of gene/environment interaction') was funded by the European Union under the 'Quality of life and management of living resources' Thematic Programme of the Fifth Framework Programme (FP5). The current study was carried out by researchers in Italy, Belgium, the Netherlands, France and the UK.

The IMMIDIET researchers, working closely with general practitioners in southwest London in England, Limburg in Belgium and Abruzzo in Italy, examined 1,604 patients. The patients underwent a comprehensive medical examination that included blood pressure measurement, and were asked to fill in a questionnaire about their lifestyle and perception of health status. They defined 'hypertension' as systolic blood pressure of at least 140mmHg or diastolic blood pressure of at least 90mmHg, or 'current antihypertensive treatment'.

The researchers were mindful of the effects of both genetic and lifestyle factors on cardiovascular disease, and recruited both married couples formed by people from the same area (Italians married with Italians in the Abruzzo region, and so forth) and mixed-nationality couples in different phases of the project.

Their findings showed, surprisingly, that high blood pressure was less common in England than in Belgium or Italy. This regional difference represents a reversal of the so-called north-south 'cardiovascular gradient'.

"This inversion is surprising," said Dr Licia Iacoviello of Italy's Catholic University of Campobasso. "It may reflect the ongoing changes of lifestyle habits. Paradoxically, northern European countries, where cardiovascular risk was higher than in Italy, are now modifying their habits, getting closer to the ancient Italian food and lifestyle culture, thus living a healthier life. [However], in Italy traditional habits are being lost, and we may be observing the negative effects on health."

Overall, the study found that awareness of hypertension was poor: 24% of study participants were hypertensive and 56% of these were unaware of their condition (one third was receiving treatment). Among those who had been diagnosed with high blood pressure, less than half had managed to bring down their blood pressure to acceptable levels.

According to Professor Francesco Cappuccio of the University of Warwick in the UK, "All national healthcare systems should do more to help control hypertension. Although in England the management of high blood pressure is better as compared to some other countries, in part due to the incentives that general practitioners receive to achieve blood pressure targets, we still have too many patients not adequately treated and the incidence of hypertension is rising still."

The IMMIDIET study also found that awareness of cardiovascular disease, hypertension in particular, is higher in women than in men. Also, women were more likely to be under treatment for hypertension, and were more successful in bringing down their blood pressure to internationally accepted 'desirable' levels. The researchers attributed this 'more successful management' to the increased willingness of women to participate in the healthcare system.

Dr Iacoviello warned, "Looking at these data and at other studies conducted in recent years, we fear Europe is facing a dangerous situation. Hypertension is a critical causative factor for serious diseases like heart attack and stroke, but it is still grossly underestimated. So we need urgent and intensive initiatives in this field, introducing new and effective strategies in controlling this threat."

Professor Cappuccio added, "This is a call for an integrated action not only on better management of hypertension but on the implementation of widespread strategies for the prevention of it in the first place."

For further information, please visit:
http://www2.warwick.ac.uk/fac/med/research/csri/cvme/immidiet

Copyright ©European Communities, 2008
Neither the Office for Official Publications of the European Communities, nor any person acting on its behalf, is responsible for the use, which might be made of the attached information. The attached information is drawn from the Community R&D Information Service (CORDIS). The CORDIS services are carried on the CORDIS Host in Luxembourg - http://cordis.europa.eu. Access to CORDIS is currently available free-of-charge.

Most Popular Now

Bayer to accelerate drug discovery with Google Clo…

Bayer AG and Google Cloud announced a collaboration to drive early drug discovery that will apply Google Cloud's Tensor Processing Units (TPUs), which are custom-develope...

NextPoint Therapeutics announces $80 million Serie…

NextPoint Therapeutics, a biotechnology company developing a new world of precision immuno-oncology, announced today that it raised $80 million in Series B financing co-l...

AstraZeneca to acquire CinCor Pharma to strengthen…

AstraZeneca has entered into a definitive agreement to acquire CinCor Pharma, Inc. (CinCor), a US-based clinical-stage biopharmaceutical company, focused on developing no...

Acquisition of Neogene Therapeutics completed

AstraZeneca has completed the acquisition of Neogene Therapeutics Inc. (Neogene), a global clinical-stage biotechnology company pioneering the discovery, development and ...

Pfizer expands 'An Accord for a Healthier World' p…

Pfizer Inc. (NYSE: PFE) announced that it has significantly expanded its commitment to An Accord for a Healthier World to offer the full portfolio of medicines and vaccin...

500,000 missed out on blood pressure lowering drug…

Nearly half a million people missed out on starting medication to lower their blood pressure during the COVID-19 pandemic, according to research supported by the British ...

Study identifies potential new approach for treati…

Targeting iron metabolism in immune system cells may offer a new approach for treating systemic lupus erythematosus (SLE) - the most common form of the chronic autoimmune...

Nanotechnology may improve gene therapy for blindn…

Using nanotechnology that enabled mRNA-based COVID-19 vaccines, a new approach to gene therapy may improve how physicians treat inherited forms of blindness. A collabo...

Roche announces the European Commission approval o…

Roche (SIX: RO, ROG; OTCQX: RHHBY) announced that the European Commission (EC) has approved Xofluza® (baloxavir marboxil) in children aged one year and above for the trea...

Modified CRISPR-based enzymes improve the prospect…

Many genetic diseases are caused by diverse mutations spread across an entire gene, and designing genome editing approaches for each patient’s mutation would be impractic...

A soybean protein blocks LDL cholesterol productio…

A protein in soybeans blocks the production of a liver enzyme involved in the metabolism of triglycerides and low-density lipoprotein, scientists found in a recent study...

Discovery of anti-cancer chemistry makes skullcap …

The evolutionary secrets that enable the medicinal herb known as barbed skullcap to produce cancer fighting compounds have been unlocked by a collaboration of UK and Chin...